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It is known that exposure to mycotoxin fumonisin B1 (FB1) causes apoptosis and increases lipid
peroxidation in the kidney of experimental animals. In this study, adult male Wistar rats were
given a single dose (5, 50, 500 mg per kg of body mass) by gavage and sacrificed 4, 24 and 48
hours after dosing. The parameters of oxidative stress, sphingolipids, DNA lesions and histo-
pathological changes were checked in the kidney of treated and control animals. The metabolism
of sphingolipids was significantly affected with the lowest FB1 dose (sphinganine/sphingosine:
2.53 ± 0.52 vs. control 0.62 ± 0.10), while even the highest dose did not change the parameters
of oxidative stress. DNA lesions measured as comet tail length (range (13.6 ± 0.41) mm to
(19.83 ± 1.43) mm) and tail intensity ((0.60 ± 0.16) % to (2.74 ± 0.17) %) were FB1 dose- and
time-dependent. Apoptotic cells and mitotic figures were found in the cortical and outer stripe














Fumonisins are a group of naturally occurring mycotox-
ins produced by the Fusarium family of moulds. They
contaminate maize and other cereals in the whole world.
Fumonisin B1 (FB1) is the most common and most toxic
fumonisin. It causes leukoencephalomalacia in horses and
pulmonary edema in pigs, as well as nephrotoxic and he-
patotoxic lesions in rats and mice. Long-term studies have
shown that it is more toxic and carcinogenic in male than
in female rats, and that kidney is the target organ of FB1
toxicity in male rats.1 Although exposure to FB1 in hu-
mans is associated with high incidence of esophageal
cancer in some regions of Africa and with primary liver
tumors in China, IARC has classified FB1 as a possible
carcinogen for humans (Group 2B) due to the lack of
epidemiological evidence.2
Most of the toxic properties of FB1 are probably re-
lated to the disruption of sphingolipid biosynthesis as the
consequence of the inhibition of ceramide synthase.3,4
Increase in free sphingoid bases, primarily sphinganine
(Sa) and sometimes of sphingosine (So), and in their ra-
tio (Sa/So) occurs in the kidney and urine and to a lesser
extent in the liver, and it may induce apoptosis.5 The
apoptotic effect of FB1 was noticed in cultured cells and
in the kidney and liver cells of experimental animals re-
ceiving high oral or intraperitoneal chronic or subchro-
nic doses of the toxin6–8 or of animals exposed to FB1
contaminated feed.9 In the kidney and liver of FB1-treat-
ed rats apoptotic and oncotic necrosis were seen as well
as a large variety of pathological changes.
The mechanism of FB1 genotoxicity is not fully un-
derstood. It has been demonstrated on various cultured
cell lines, and some authors have associated it with ROS
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production and/or lipid peroxidation.10–13 Other authors
have shown that ROS follows the production of DNA le-
sions, thus indicating that the effects of FB1 are not the
result of oxidative injury but the response that may occur
after modulation of protective genes.14,15 In our previous
study on rats using the comet assay, we have shown that
repeated FB1 dosing causes DNA lesions in rat kidney.16
Earlier studies have shown that FB1 is not acutely
toxic,17 and some reversible toxic effects in experimen-
tal animals are obtained only with very high doses.18
The aim of this study was to find out whether a single
FB1 dose can produce oxidative stress, disturbance of
sphingolipid metabolism, DNA damage and apoptosis in
rat kidney shortly after administration.
EXPERIMENTAL
Animal Treatment
Adult male Wistar rats (mass ≈ 230 g) exposed to a light/
dark cycle of 12 h and constant temperature of 24 °C were
kept in macrolone cages. Animals were fed on a standard
diet for laboratory rodents (Mucedola, Settimo Milanese,
Italy) and had free access to water.
The rats were randomized in ten (nine exposed plus one
control) groups of six animals each. Each group was gavag-
ed a different single FB1 dose (5, 50 or 500 mg/kg of body
mass) dissolved in sterile saline (9 g NaCl per 1 L H2O) or
solvent only (control animals). FB1 (98 % purity) was pur-
chased from Sigma Chemicals (St. Louis, MO, USA).
The animals were killed by cervical dislocation 4, 24
and 48 hours after dosing. Kidneys were collected and wash-
ed in saline. One kidney was immersed into a 4 % buffered
formaldehyde solution for histology. The comet assay was
performed immediately, while the tissue samples for the bio-
chemical analyses were stored at –20 °C.
The principles of good laboratory animal care were fol-
lowed throughout, as well as the 2007 Croatian Animal
Welfare Act. The Institute’s Ethical Committee approved the
study.
Biochemical Assays
Kidney homogenates (10 g per 100 ml buffer) were prepared
for biochemical assays in chilled 0.05 mol dm–3 potassium
phosphate buffer (pH = 7.4).
Reduced glutathione (GSH) was measured in superna-
tants of the kidney homogenates using Ellman’s method.19
In 0.1 ml of sample 0.85 ml of 0.3 mol dm–3 phosphate buf-
fer, pH = 7.4, and 0.05 ml of 10 mmol dm–3 5,5'-dithio-
bis(2-nitrobenzoic acid) (DTNB) were added. The reaction
was read at 412 nm and the results were expressed as
(n(GSH)/mmol) / (m(protein)/mg).
The concentrations of malondialdehyde (MDA) were
measured in kidney homogenates spectrophotometrically at
532 nm using the method of Drury et al.20 Briefly, 1 %
o-phosphoric acid (0.75 ml), 0.6 g thiobarbituric acid per
100 ml H2O (0.25 ml) and redistilled water (0.445 ml) were
added to 0.05 ml sample aliquots which were then heated in
water bath at 95 °C for 20 min. After cooling, samples and
MDA standards were read against blanks at 532 nm. The
concentrations were determined using standard MDA cur-
ves, and the results were expressed as (n(MDA)/nmol) /
(m(protein)/mg).
Protein concentration was determined according to
Bradford.21
The mass fraction of sphingolipids were determined in
the same kidney homogenates according to method describ-
ed by Shephard and van der Westhuizen.22 Sphingolipids
were derivatized with o-phthaldialdehyde. An aliquot was
injected onto an HPLC with fluorescent detection (Varian
Walnut-Creek, USA), and chromatograms were analyzed
using the Varian Star Chromatography Workstation Ver. 5.0
(Varian Walnut-Creek, USA).
Alkaline Comet Assay
Kidney tissue samples for the comet assay were homoge-
nized in a chilled homogenization buffer (pH = 7.5) con-
taining 75 mmol dm–3 NaCl and 24 mmol dm–3 Na2EDTA
to obtain a 10 g / 100 ml buffer tissue solution. A Potter-
type homogenizer was used.23
We used alkaline comet assay protocol according to
Sasaki et al.23 6 ml of kidney homogenate were suspended
in low-melting agarose (0.5 g in 100 ml TBS) and sand-
wiched between a layer of normal-melting agarose (0.6 g in
100 ml TBS) and a top layer of low melting agarose (0.5 g
in 100 ml TBS) on fully frosted slides. The slides were kept
on ice during the polymerization of each gel-layer. After
the solidification of the normal-melting agarose layer, the
slides were immersed in a lysis solution (34.1 mmol dm–3
sodium sarcosinate, 2.5 mol dm–3 NaCl, 100 mmol dm–3
Na2EDTA, 10 mmol dm–3 Tris-HCl, 1 % (vol. fraction)
Triton X-100 and 10 % (vol. fraction) DMSO) at 4 °C. Af-
ter one hour, the slides were placed into an electrophoresis
buffer (0.3 mol dm–3 NaOH, 1 mmol dm–3 Na2EDTA, pH =
13) for 10 minutes at 0 °C to allow for the DNA to unwind.
Electrophoresis was performed for 10 minutes at 300 mA
and 1 V/cm. The slides were neutralized with a Tris-HCl
buffer (pH = 7.5) and stained with ethidium bromide (20
mg/ml) for 10 minutes. Each slide was analyzed using the
Leitz Orthoplan epifluorescence microscope. One hundred
cells were analyzed on each slide using the comet assay II
automatic digital analysis system (Perceptive Instruments
Ltd., Suffolk, Halstead, UK) to determine the tail length and
tail intensity. Tail length (expressed in mm) is the distance
of DNA migration from the center of the body of the nu-
clear core and it is used to evaluate the extent of DNA da-
mage. Tail intensity (expressed in percents) is the fraction
of the genomic DNA that migrated during the electropho-
resis from the nuclear core to the tail. Both, tail length and
tail intensity are measured automatically by image analysis
software.
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Histopathology
After fixation kidney tissues were dehydrated through an
ethanol series, treated with xylene and embedded into pa-
raffin. 3 ìm thick sections were stained with Periodic acid
Schiff stain (PAS). The number of cells undergoing apop-
tosis and mitotic figures were determined by counting the
number of apoptotic or mitotic cells in the outer stripe of
the outer medulla and in the cortex of rat kidney on 10
randomly selected high power microscopic fields (400x).
Statistical Analysis
Differences in biochemical parameters (concentration of Sa,
So and their ratio, MDA, and GSH) in kidney tissues of
treated and control animals and between different groups
were tested using the Student’s t-test for independent sam-
ples using Statistica 5.0.
Possible differences in the comet assay endpoints in tis-
sue samples were evaluated using the Kruskal-Wallis non-
parametric test. We also analyzed differences between treat-
ment times and doses.
Probability values of P<0.05 were considered statisti-
cally significant.
RESULTS AND DISCUSSION
In the kidney tissues of all FB1-treated groups, GSH and
MDA concentration did not change as compared to con-
trols (data not shown). These results are in accordance
with the study of Bondy et al.24 in rats treated with FB1
(7.5 or 10 mg/kg b.m., i.p.) for four consecutive days as
well as with our previous study where rats were given FB1
dose of 0.5 mg/kg b.m., i.p. for two days.25 Our results
confirm that oxidative stress is the consequence of rather
than a step in the mechanism of FB1 toxicity.14,15,26
Numerous studies have demonstrated that FB1 inhi-
bits enzyme ceramide synthase in the kidney, with a con-
sequent increase in Sa concentration and Sa/So ratio.4
Repeated FB1 dosing (50 mg/kg diet for 10 days) increa-
ses the Sa concentration over 100 times in the kidney.3
Other authors claimed that the lowest dose of FB1 which
induced a change in Sa/So ratio in any tissue was 1.0 mg/kg
of b.m., p.o. (5 days a week per 5 weeks).27 However, in
our study mentioned above, the increase in Sa and So mass
fractions, as well as the increase in Sa/So ratio was no-
ticed even after two treatments with 0.5 mg/kg b.m., i.p.25
In our experiment the mass fraction of Sa and Sa/So ra-
tio were significantly higher than in controls (Table I).
This effect was noticed with all applied doses, and ap-
peared in the first four hours after dosing, indicating that
this biomarker was more sensitive than was believed
earlier.
Studies of FB1 genotoxicity are rather scarce and are
mostly performed on cell cultures. A single study perform-
ed using a kidney cell line was published by Rumora et
al.28 The authors observed concentration- and time-de-
pendent induction of micronuclei in rabbit kidney RK13
cells. Positive results on genotoxicity testing were also
obtained by Kouadio et al.13 on intestinal cell line CaCo-2,
Ehrlich et al.29 on human derived hepatoma HepG2 cells,
and Galvano et al.15 on human fibroblasts. We showed
earlier that a two-day treatment with 0.5 mg/kg of body
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Figure 1. (a) Control animal. There is normal morphology of the
cortical part of the kidney. (b) Animal treated with FB1. One mito-
tic figure is seen in the cortical part of the kidney (arrow). (c) Ani-
mal treated with FB1. Two apoptotic cells are seen in the cortical




mass, i.p. increased the comet assay tail length and tail
intensity in the rat kidney cells.25 This is the first report
on the use of comet assay in the kidney of rats treated
with a single FB1 dose (Table II). The lowest dose did
not increase tail length, but it did increase tail intensity
in rats sacrificed 24 and 48 hours after treatment. This
difference in the response of comet parameters is not
surprising since tail intensity is considered to be a more
sensitive marker of DNA damage. In general, higher
doses of FB1 caused earlier appearance of DNA lesions
than lower doses. Our results showed clearly that the ge-
notoxic effect of FB1 is time- and dose-dependent, and
that it may be achieved by a single oral dose.
Histopathological changes caused by FB1 in this study
were milder but consistent with previous studies obtain-
ed with higher doses and longer exposure times.6,9,30 In
other studies, treatment with high doses of FB1 (15–75
mg/kg b.m., p.o. for 11 days), in addition to apoptotic cells
and mitotic figures, also caused dose-related necrosis,
sloughing of tubular epithelial cells in the inner cortex,
anisokaryosis, cytoplasmic basophilia and atrophy of tu-
bular epithelial cells.6 When shorter i.p. treatment (4 days)
with lower FB1 doses (7.5 and 10 mg/kg b.m.) was ap-
plied, minimal renal lesions with rare single-cell necrosis
and desquamation of epithelial cells were seen.24 How-
ever, the most prominent finding in the kidney of male
rats exposed to FB1-contaminated feed (99, 163, 234, and
484 mg/kg b.m.) for 28 days were apoptosis and mitotic
figures in the inner cortex.9 All treated rats had essential-
ly the same level of apoptosis, and except for the 99 mg/kg
dose group, an equivalent severity of kidney degenera-
tion was reported. The lack of the difference in the se-
verity of kidney lesion between groups of rats treated for
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TABLE II. Tail length and tail intensity(a) in the kidney of rats (mean
± S.E.; N = 6) treated with single FB1 dose(b) and sacrificed 4, 24









0 13.4 ± 0.05 0.42 ± 0.06
5 4 13.6 ± 0.41 0.60 ± 0.16
24 14.5 ± 0.40 (1.33 ± 0.22)(c),(d)
48 14.8 ± 0.50 (1.80 ± 0.19)(c),(d)
50 4 14.3 ± 0.30 (1.21 ± 0.27)(c)
24 (15.3 ± 0.39)(c),(f) (1.63 ± 0.08)(c)
48 (16.8 ± 0.56)(c),(d) (1.80 ± 0.25)(c)
500 4 14.2 ± 0.22 (1.66 ± 0.19)(c),(f)
24 (16.5 ± 0.51)(c),(d),(e) (1.24 ± 0.22)(c)
48 (19.83 ± 1.43)(c),(d),(e) (2.74 ± 0.17)(c)-(g)
(a) Tail length is the distance of DNA migration from the center of the
body of the nuclear core. Tail intensity is the fraction of the genomic
DNA that migrated during the electrophoresis from the nuclear core to
the tail.
(b) m(FB1): 5, 50 and 500 mg per kg of body mass.
(c) Different from controls.
(d) Different from 4 hours exposure.
(e) Different from 24 hours exposure.
(f) Different from 5 mg/kg b.m. dose.
(g) Different from 50 mg/kg b.m. dose (P<0.05).
TABLE I. Mass fraction (w) of sphingosine (So) and sphinganine (Sa)(a) and Sa/So ratio in kidney tissue of rats (mean ± S.E.; N = 6)
treated with single dose of FB1(b) and sacrificed 4, 24 and 48 hours after treatment (t)
m(FB1) / mg t / h w(So) · 106 w(Sa) · 106 w(Sa) / w(So)
0 8.36 ± 3.33 4.89 ± 1.82 0.62 ± 0.10
5 4 13.14 ± 5.46 (30.72 ± 11.11) (c) (2.53 ± 0.52) (c)
24 25.08 ± 5.41 (72.03 ± 17.22) (c) (2.93 ± 0.42) (c)
48 21.40 ± 4.61 (29.65 ± 6.50) (c) (1.44 ± 0.13) (c),(e)
50 4 11.63 ± 0.70 (35.56 ± 3.72) (c) (3.14 ± 0.44) (c)
24 11.08 ± 0.42 (32.36 ± 2.92) (c) (2.95 ± 0.30) (c)
48 7.30 ± 1.52 (16.04 ± 3.69) (c) (2.17 ± 0.35) (c)
500 4 11.19 ± 3.32 (21.63 ± 6.29) (c) (1.99 ± 0.20) (c)
24 35.69 ± 5.89 (88.00 ± 28.77) (c),(d) (2.22 ± 0.33) (c)
48 20.29 ± 6.89 (80.58 ± 27.45) (c),(d),(g) (5.54 ± 1.18) (c)-(g)
(a) w(sphingolipids) = (m(sphingolipids)/ng) / (m(tissue)/mg).
(b) m(FB1): 5, 50 and 500 mg per kg of body mass.
(c) Different from controls.
(d) Different from 4 hours exposure.
(e) Different from 24 hours exposure.
(f) Different from 5 mg dose per kg b.m.
(g) Different from 50 mg dose per kg b.m. (P < 0.05).
four and 13 weeks was also noticed in animals fed with
FB1 contaminated feed (9, 27, 81 mg/kg).31 In our study,
histopathological changes included the appearance of
apoptotic cells and mitotic figures in the cortical part of
the kidney as well as in the outer stripe of medulla (Fig-
ure 1). The number of apoptotic cells and mitotic figures
was higher than in controls, but their appearance was not
clearly dose- and time-related, which is similar to the study
of Tolleson and co-workers.9 Although it is known that
FB1 stimulates degenerative and regenerative processes
in the kidney, the co-occurrence of apoptosis and mitotic
figures both in the cortical and medullar part of the kidney
are surprising because they indicate that these processes
occur even after a single FB1 dose.
CONCLUSION
The major finding of this study was that the single dose
of FB1 in rats disturbs the sphingolipid metabolism even
after a very short period of exposure. DNA lesions occur
after longer exposure to the lowest dose, but they are time-
and dose-dependent. Apoptotic cells and mitotic figures
seen in all treated groups indicate the high potential of
FB1 to produce degenerative and regenerative processes,
probably due to changes in sphingolipid metabolism.
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SA@ETAK
U~inak jednokratne doze fumonizina B1 na bubreg {takora
Maja Peraica, Danica Ljubanovi}, Davor @elje`i} i Ana-Marija Domijan
Mikotoksin fumonizin B1 (FB1) u pokusnih `ivotinja uzrokuje apoptozu i pove}anu lipidnu peroksidaciju
u bubrezima i jetri. U ovom istra`ivanju odrasli mu`jaci {takora soja Wistar tretirani su jednokratnom dozom
FB1 (5, 50, 500 mg/kg tjelesne mase) i `rtvovani 4, 24 i 48 sati nakon tretmana. Parametri oksidacijskog stresa,
koncentracija sfingolipida, o{te}enja DNA i histopatolo{ke promjene pra}ene su u bubregu tretiranih i kontrol-
nih `ivotinja. Tretman s FB1 zna~ajno je poremetio metabolizam sfingolipida ve} i pri najmanjoj primijenjenoj
dozi (Sa/So: 2,53 ± 0,52; kontrola 0,62 ± 0,10), dok ni najve}a doza nije uzrokovala promjene parametara oksi-
dacijskog o{te}enja. Ovim istra`ivanjem dokazano je da jednokratna doza FB1 uzrokuje o{te}enje DNA koje je
ovisno o duljini izlo`enosti i dozi (du`ina repa: (13,6 ± 0,41) mm do (19,83 ± 1,43) mm; intenzitet repa: (0,60 ±
0,16) % do (2,74 ± 0,17) %). Apoptoti~ne stanice i stanice u mitozi na|ene su u kortikalnom i medularnom
dijelu bubrega svih tretiranih `ivotinja.
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